Obviously the staff reduction included people [pharmavigilance & such] working on the trial. Command was the major activity of the company. I don't expect to hear much from management until they finalize their plans. Hopefully to include a research partnership.
Don't know if the price reflects a loss of confidence or complete disappointment. Some companies, such as Infinity, have had many failures & still retain investor confidence. I don't know of any other $70 million biotech with over $100million & Verastems exposure. Prior to the offering my recommendation was that they add a research partner. This would have enabled a higher price - particularly if the partner participated in the offering. Instead they sold stock into the open market prior to the offering! Boston Biomedical & OncoMed are examples of csc that that made deals early. VSTM is still determined to go it alone. Near term it would be interesting to know the new owners of the stock & of course the results of the ovarian trial.
A private company, so far, that is focusing on CSC recently raised additional money. The list of backers of Stemcentrix & the capitalization are quite interesting.
The interesting session was Sunday 5/31. As Dr. Wicha has been involved in csc research for a long time his remarks were particularly interesting. Immunotherapies will need to be combined with csc therapies. His comments on the importance of FAK inhibitors position as a key mode. Not new , the addition of csc by some oncology drugs. A lot going on.
I wish all those fighting cancer success. Nothing is proved [immunotherapy] on solid tumors. I do know that custom treatments like this are fantasticality expensive. Perhaps the first csc drug to market will attract attention.
The price was certainly lower than expected. Many biotechs have been raising $ since the first of the year. No pre offering stockholder has a profit. The ones in shock are those who participated in the original offerings [$10 & $15] & saw 3 years of progress. However, this is part of the risk investing in any venture capital [no product, no cash flow] firm. The stock looks attractive here on a risk-reward & timing [operational] basis. Looking for positives: money in hand early, $ until 2017, insiders participated, company retained 100% of benefits.
The thing that received my attention was the number of leads,teasers, that have resulted from their ongoing work. The company went public exactly 3 years ago @ $10. I wonder what it would sell for if going public for the first time now. Certainly more than the present price. I do recall that the base for Genzyme was also an orphan drug.
The excellent work being done by research organizations continue to show the negative effects of CSC in oncology. However, substantial work will be necessary to provide aid to the patients.
If a director would recommend when next raising $ selling stock, at a premium, directly to a larger company & joining in a research collaboration.
The recent presentation in London was well done. If you can decipher the accent it is worth a listen.
The excellent work being done by research organizations reinforces the known negative effects of CSC in oncology. However, substantial work is necessary to provide aid to the patients.
If a director would recommend when next raising $ sell stock, at a premium, to a larger company & join in a research collaboration.
The recent presentation, in London, was well done. If you can decipher the accent it is worth a listen.
A long shot - mostly for knowledge. They admit it is a [high hurdle]. Give them credit they will tell it , good or bad, as it is.
There is a reasonable chance they will have the first drug in the CSC area. This should attract attention to the company [they do have impressive professional contacts for a $200 million company]. Beyond that they have to determine what works when & where. I believe the upside is substantial if things work out. Prefer the company to Stemline on an operating basis & to OMED on a cap basis.
Yes - I like it on a long term basis. Will answer your question in more detail later. When allocating $ the small biotech's are essentially venture capital companies. Today I am focused on the general market - may be setting up for an opportunity. Forget the blah, blah on CNBC. They will look back at a higher stock market & the why will be obvious. The substantial amount of money to be continually invested. Sovereign funds, hedge funds, mutual funds, colleges, museums, family trusts, money seeking safe haven from every corner of the world, illegal money, etc, etc. With increasing interest rates fixed income will be less interesting.
Realize that this is a relatively thin stock - but the day to day price action is strange. It is obvious that a large holder[s] is selling. Individuals are not the only ones buying high & selling low. On R & D Day - numerous institutions are doing good work on CSC. An update would be helpful.
With the ipo in early 2012 @$10 & a secondary @$15 no holder has a profit. I wonder where the stock for sale is coming from. With the progress in two years & the stock at a discount it looks interesting. Evidently the directors don't agree.
Agree with bat on valuation. I can list biotechs @ $400mm +that have no better research profile than astex ($220mm}. Also, most will need $ in the next year or so.
The only other small company,that I am aware of, working with second generation Hsp-90 is Synta [s nta]. You may find the transcript of yesterdays conference call interesting.
The only other small company,that I am aware of, working on second generation Hsp-90 is Synta(snta) . You may find the transcript of yesterdays conference call of interest.
An opportune time for the company to buy in stock at a deep discount from asset value.
If you are interested in Bakkem - for more detail (well permits, etc}
Looking @ the company for the first time. In theory the 16 product candidates with the FDA could result in one a month for an extended period. My question - historically is this more candidates than usual or is it the nature of the business?